Patent 11434489 was granted and assigned to Skyhawk Therapeutics on September, 2022 by the United States Patent and Trademark Office.
Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.